Company Monitoring Page for Astellas

latest headlines for company on cafepharma

Audentes sees FDA hold lifted after 3 trial deaths blighted $3B program
Fierce Biotech
Mon, 12/28/20 - 10:59 am
Tags:
Audentes, Astellas, FDA, clinical trials, AT132, gene therapy, X-linked myotubular myopathy
Astellas, FibroGen get approval in Japan for Evrenzo to treat anaemia of CKD in adult patients not on dialysis
Pharmaceutical Business Review
Sun, 11/29/20 - 02:10 pm
Tags:
Astellas, FibroGen, Japan, Evrenzo, chronic kidney disease
Fancy a Black Friday R&D deal? Astellas has you covered
Fierce Biotech
Wed, 11/25/20 - 10:34 am
Tags:
Astellas, R&D
$200M investment to advance clinical programs for Ambrx
MedCity News
Mon, 11/23/20 - 10:18 pm
Tags:
Ambrx, oncology, Astellas, BeiGene, Bristol-Myers Squibb
In early blow to Kenji Yasukawa's R&D revamp, Astellas drops out of the TIGIT race without explanation
Endpoints
Fri, 10/30/20 - 10:17 am
Tags:
Astellas, earnings, anti-TIGIT, R&D
A Year After Partnering with iota, Astellas Snaps Up the Company
BioSpace
Thu, 10/15/20 - 12:27 pm
Tags:
Astellas, iota Biosciences, bioelectronics
Seagen, Astellas report positive results from PADCEV phase 2 trial in advanced urothelial cancer
Pharmaceutical Business Review
Tue, 10/13/20 - 11:08 am
Tags:
Seagen, Astellas, clinical trials, EV-201, urothelial cancer
Seattle Genetics stays step ahead of rivals with bladder cancer data
BioPharma Dive
Sat, 09/19/20 - 09:04 pm
Tags:
Seattle Genetics, Astellas, Padcev, bladder cancer, clinical trials, ESMO
Astellas puts health inequality front and center in cancer innovation challenge's 5th year
Fierce Pharma
Tue, 09/1/20 - 10:34 pm
Tags:
Astellas, oncology, innovation, innovation challenges
Astellas' Audentes reports 3rd death in gene therapy trial
Fierce Biotech
Fri, 08/21/20 - 12:11 pm
Tags:
Audentes Therapeutics, Astellas, clinical trials, gene therapy, patient deaths, AT132
GSK’s kidney disease anemia drug approved in Japan, taking on Astellas’ rival
Pharmaforum
Mon, 06/29/20 - 06:21 pm
Tags:
GSK, anemia, chronic kidney disease, daprodustat, Japan, Astellas, Kyowa Kirin
With cell and gene therapy boom coming, experts at Novartis, Kite trumpet need for capacity: panel
Fierce Pharma
Wed, 06/24/20 - 11:21 pm
Tags:
cell therapy, gene therapy, Novartis, Kite Pharma, Biomarin, Astellas
Astellas' Anemia Drug Roxadustat Shows Non-Inferiority to Amgen's Aranesp
BioSpace
Mon, 06/8/20 - 11:36 pm
Tags:
Astellas, clinical trials, roxadustat, Amgen, Aranesp, anemia, chronic kidney disease
ASCO: Pfizer, Astellas show Xtandi helps early prostate cancer patients live longer
Fierce Pharma
Thu, 05/14/20 - 10:15 am
Tags:
ASCO 2020, Pfizer, Astellas, Xtandi, castration-resistant prostate cancer
Harvard pens Astellas research deal, vowing to push on despite pandemic
Fierce Biotech
Tue, 04/28/20 - 11:48 pm
Tags:
Harvard, Astellas, R&D, COVID-19
Go or no go? Covid-19 upstages US regulatory decisions
EP Vantage
Tue, 03/24/20 - 10:30 am
Tags:
FDA, regulatory, Bristol-Myers Squibb, ozanimod, Esteve, E-58425, Fabre-Kramer, AstraZeneca, Imfinzi, Astellas, Vesicare, AbbVie, Neurocrine, Orlissa, Sanofi, MenQuadfi, opicapone, Acceleron, Reblozyl
CytomX pens $1.6B Astellas biobucks pact for T-cell R&D
Fierce Biotech
Tue, 03/24/20 - 10:22 am
Tags:
Astellas, CytomX, R&D
Pharma New Astellas, Seattle Genetics Padcev combo data spark $5.8B sales hopes
Fierce Pharma
Fri, 02/14/20 - 05:07 pm
Tags:
Astellas, Seattle Genetics, Padcev, advanced bladder cancer, bladder cancer
Pfizer and Astellas Report Positive OS Data in Prostate Cancer Study
BioSpace
Tue, 02/11/20 - 11:45 pm
Tags:
Pfizer, Astellas, prostate cancer, metastatic castration-resistant prostate cancer, Xtandi
Seattle Genetics, Astellas Says 73% Of Bladder Cancer Patients On Padcev Had Confirmed Tumor Response
Reuters
Tue, 02/11/20 - 10:46 am
Tags:
Seattle Genetics, Astellas, bladder cancer, Padcev

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.